Long COVID After Bamlanivimab Treatment

By sjmartinez • August 31, 2023

Evering TH, Moser CB, Jilg N, Yeh E, Sanusi B, Wohl DA, Daar ES, Li JZ, Klekotka P, Javan AC, Eron JJ, Currier JS, Hughes MD, Smith DM, Chew KW; ACTIV-2/A5401 Study Team. Long COVID After Bamlanivimab Treatment. J Infect Dis. 2023 Aug 31;228(Supplement_2):S126-S135. doi: 10.1093/infdis/jiad286. PMID: 37650236.

Tags: bamlanivimab, Clinical Trial, Harbor UCLA, Infectious Diseases, long COVID, postacute sequelae of SARS-CoV-2 infection (PASC), Publications, symptom

When Is Enough Enough? Additional Evidence of the Power of Zero

Budoff MJ. When Is Enough Enough? Additional Evidence of the Power of Zero. Circ Cardiovasc Imaging. 2024 Dec 20:e017714. doi: 10.1161/CIRCIMAGING.124.017714. Epub ahead of print.[...]

“Anti-inflammatory Therapies in Atherosclerosis – Where are we going?”

Punnanithinont N, Kambalapalli S, Iskander B, Ichikawa K, Krishnan S, Lakshmanan S, Roy SK, Budoff M. "Anti-inflammatory Therapies in Atherosclerosis - Where are we going?".[...]

Retrospective Study of CD20 Expression Loss in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Marshalek JP, Qing X, Dragan M, Tomassetti S. Retrospective Study of CD20 Expression Loss in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. J Hematol. 2024 Dec;13(6):268-277.[...]